42% of patients developed sepsis within 1 year. 4 Infections directly related to a VAD have been estimated to occur in 14% to 59% of cases. 3, [5] [6] [7] Numerous pathogens, most commonly staphylococci, cause VAD infections. 6 VAD infections often involve the percutaneous driveline but may also involve the pump pocket, the pump and/or cannula, the pump interior, the sternal wound, and the bloodstream. 8 Multiple sites are often infected. Systemic infections appear to be associated with higher mortality than local infections. 6 Despite the high incidence and potential increased morbidity and mortality associated with VAD infections, the epidemiology has not been well described. Prior studies have been limited by sample size or retrospective and/or single-center design and have used variable definitions of device infection. There is a lack of large, multicenter studies with prospectively collected data focused on carefully identifying and characterizing these infections and describing their microbiology, epidemiology, risk factors, and outcomes. 6 This study was designed to fill this gap because these data are needed to better diagnose, further study, treat, and prevent VAD infections.
Methods

Study Design
Eleven US clinical centers participated in this study between January 2006 and 2009. The International Center for Health Outcomes and Innovation Research at Columbia University coordinated enrollment and data collection, monitored data quality, and provided statistical support. Study procedures were standardized across sites according to the protocol. Data were entered into a centralized, secure, electronic data capture system. Each site received Institutional Review Board approval, and subjects gave written informed consent and signed a Health Insurance Portability and Accountability Act release.
Study Subjects
Patients ≥18 years of age approved to receive a VAD for either DT or as a bridge to transplantation were eligible to enroll. Subjects were monitored for infection until explantation or up to 1 year. Subjects who underwent device replacement remained in the study.
Data Collection and Adjudication
Baseline data included demographics, medical history, details of a physical examination performed within 2 weeks of VAD implantation, and a comprehensive laboratory assessment performed within 24 hours before surgery. Information on infections, their microbiology, and treatment within 30 days before surgery was also recorded.
Variables collected on the VAD surgery included the type and location of VAD(s), cardiopulmonary bypass time, and quantities of infused blood products. Details of the index hospitalization were recorded, including days in the intensive care unit, as were subsequent hospitalizations and surgeries. Clinical sites reported noninfection adverse events using the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) definitions. 9 When a patient was transplanted or explanted, the VAD was inspected for signs of infection and cultured if applicable. VADs were examined for evidence of infection when autopsies were performed.
A "clinical infection assessment" was conducted whenever there was clinical suspicion of infection, fever >38.3°C after postoperative day 3, or the addition of nonprophylactic antibiotics. Assessments included vital signs, routine laboratory testing, examination of the driveline exit site, the pump pocket, and the sternal wound, as well as the results of blood or other applicable cultures. Administered antibiotics were recorded. Within a week of the initiation of the infection assessment, the clinical center answered the question, "Was the clinical impression that a VAD infection was present?" If the answer was "uncertain" or "yes," then the infected sites were specified.
An infectious diseases specialist (R.J.G.) reviewed all available data, including source documentation, from all clinical infection assessments. Clinical, microbiological, and histopathological data were used to diagnose VAD infections, to verify the date of infection, and to describe which parts of the device were infected with what microorganism(s). Specific predefined criteria were used to confirm infections, including a combination of positive cultures (often multiple) from ≥1 sites, purulent fluid (eg, neutrophils) in the pump pocket, gross or histopathological evidence of infection on device removal or pump pocket exploration, excess and/or abnormal drainage from the driveline exit site, and local signs of infection (erythema, pain, swelling, wound dehiscence, and nonintegration of the driveline). Systemic signs of infection (eg, sepsis, fever, and leukocytosis) and antibiotic treatment frequently supported the diagnosis. If there was disagreement between the first specialist and the clinical center, a second infectious diseases specialist (F.D.L) determined the outcome. Details of other healthcare-associated infections such as pneumonias, urinary tract infections, Clostridium difficile colitis, wound infections, and non-VAD-related bloodstream infections (BSIs) were also evaluated.
Statistics
The Kaplan-Meier product-limit estimate 10 was used to explore time to first VAD infection. The log-rank test was used to compare differences among groups. In addition, Cox proportional hazards regression models 11 were used to explore univariate and multivariable associations between potential risk factors and VAD infection. Patients who did not experience VAD infections were censored if they died, withdrew, or were transplanted, explanted for recovery, or lost to follow-up. Covariates with values of P<0.15 in the univariate model were individually tested in the multivariable model in a manual stepwise procedure to explore potential associations, collinearity, confounding, and relevant interactions. Hazard ratios (HRs) with 95% confidence intervals (CIs) were generated, and HRs for continuous variables are expressed per unit change. The hazard function with 95% CIs was plotted to demonstrate the instantaneous risk of infection over the study period. 12, 13 The main multivariable model and a HeartMate II subgroup analysis included different covariates. Two of 150 subjects had missing values in the main multivariable model, and 4 of 85 subjects had missing values in the subgroup analysis. A sensitivity analysis was performed using an expectation-maximization algorithm to estimate these missing values, which supported the study findings. Subjects with missing values have been excluded from the figures and tables.
A Cox proportional hazards model was also used to investigate the effect of infection on 1-year mortality. Other adverse events were examined as time-dependent variables.
A competing-risks analysis was performed to calculate the cumulative incidence of the 4 major VAD surgery outcomes (alive with device, transplanted, explanted, and died), stratified by infection status. P values were not adjusted for multiple comparisons and inflation of the type I error. SAS software version 9.1.3 (SAS Institute Inc, Cary, NC) was used to perform all analyses.
Results
Characteristics of Study Participants
One hundred fifty patients with advanced HF approved for VAD implantation were enrolled at 11 cardiac centers (1-29 patients per center; Table I in the online-only Data Supplement). Study subjects are described in Table 1 . The mean age at enrollment was 54±13 years; 126 (84%) were male, 101 (67%) were white, and 32 (21%) were black.
Seventy subjects (47%) were listed with the United Network for Organ Sharing for potential cardiac transplantation.
Fifty-three percent had ischemic HF. The previous cardiac history of the cohort included 72 (48%) with myocardial infarction, 51 (34%) with coronary artery bypass graft surgery, 44 (29%) with percutaneous coronary intervention, 66 (44%) with atrial fibrillation, 63 (42%) with ventricular arrhythmia, and 20 (13%) with a prosthetic valve(s). Other comorbidities such as diabetes mellitus (36%) and chronic renal insufficiency (30%) were common. Given the severity of illness in the population, many were receiving circulatory or ventilatory support before VAD implantation (eg, 25% had an intra-aortic balloon pump).
Baseline physical examination findings and laboratory values are listed in Table 2 . This ill population had evidence of both renal and hepatic dysfunction. Poor nutritional status was common; 51% had serum albumin <3.4 g/dL, and 18% were described as cachectic on physical examination. Twenty-five percent were obese.
In the month before surgery, 38 (25%) were diagnosed with at least 1 infection, and 58 (39%) received at least 1 antibiotic. Preimplantation infections included BSIs (n=10, 5 catheter related), pneumonias (n=8), urinary tract infections (n=15), wound infections (n=3), and C difficile colitis (n=2). Antibiotics were given to treat these infections, as empirical therapy without a confirmed infection or as preprocedural prophylaxis.
VAD Surgery
The median duration of VAD support was 244 days. One hundred forty-five patients underwent univentricular left VAD support. These included HeartMate II (n=85), Heart-Mate I (n=50), Thoratec Implantable Ventricular Assist Device (n=5), VentrAssist (n=3; Ventracor Ltd, Chatswood, New South Wales), and Novacor (n=2; WorldHeart Inc, Salt Lake City, UT). Five patients received biventricular support: Implantable VADs were placed in the "preperitoneal" space (n=117), abdomen (n=27), or left thorax (n=1) (not reported, n=2). The median total cardiopulmonary bypass time was 87 minutes (range, 10-341 minutes). Exogenous blood products were administered to 140 patients, and the cell saver alone was used in 10 patients. The following blood products were administered: packed red blood cells (mean±SD, 4.3+4.6; range, 0-27), platelets (mean±SD, 8.6+10.5; range, 0-50), freshfrozen plasma (mean±SD, 4.7+4.3; range, 0-22), and cryoprecipitate (mean±SD, 4.1+8.2; range, 0-50). Perioperative antibiotics were administered but varied considerably within and among the clinical centers.
Adverse Events
Numerous serious adverse events occurred before VAD infection or study termination: major bleeding (44%), respiratory failure (21%), neurological events (16%), renal failure (12%), right-side HF (7%), device malfunction (7%), and hepatic dysfunction (3%). Several subjects had multiple adverse events, including repeated episodes of the same event such as bleeding ( Table II in the online-only Data Supplement). Two patients with a HeartMate I and 1 patient with a HeartMate II required device replacement for pump failure and thrombosis, respectively, at ≈10 to 11 months after implantation.
Fifty-eight patients (39%) experienced non-VAD-related infections, including urinary tract infections (15%), BSIs (13%), pneumonias (13%), wound infections (4%), and C difficile colitis (6%). Patients often experienced multiple infections ( Table III in 
VAD Infections
Thirty-three patients (22%) experienced 34 VAD infections ( Table 3 and Figure 1 ) with an incidence rate of 0.10 VAD infections per 100 patient-days (95% CI, 0.073-0.142). The median time to first infection was 68 days. The hazard function ( Figure 2 ) illustrates that the risk of VAD infection peaked at 18 days after surgery and was lower and fairly constant after 60 days. At least 28 of the 34 infections involved the VAD driveline (82%); however, most infections also involved other sites such as the pump pocket, pump housing, and bloodstream. Almost half of all infections (n=16) were associated with BSIs, some of which were complicated by septic emboli.
The microbiology of VAD infections varied, but Grampositive organisms predominated. Coagulase-negative staphylococci were involved in 9 infections. Staphylococcus aureus caused 7 infections. Enterococci or viridans streptococci caused 5 infections. There were 5 infections with Pseudomonas aeruginosa, and assorted enteric Gram-negative pathogens caused several others. Five infections were polymicrobial. One infection was due to yeast (Candida glabrata). This infection resulted in graft erosion, exsanguination, and death. Three infections were culture negative, each with strong clinical or histopathological evidence of infection and previous exposure to antibiotics.
Infections occurred at 8 of the 11 centers and did not vary by geographic location (western, midwestern, eastern; Table  I in the online-only Data Supplement). The 3 centers without any infections enrolled ≤6 subjects. At centers with infections, 10% to 40% of patients experienced a VAD infection. There were no major associations between microbiology and clinical center, nor were there trends in time to infection by clinical center or microorganism. 
Univariate Analysis
In univariate analysis (Table 1) , a history of depression and renal insufficiency were associated with VAD infection. Higher baseline serum creatinine and total bilirubin were also associated with VAD infection ( Having an infection or receiving antibiotics within the month before VAD implantation also did not affect the risk of infection on VAD support. Furthermore, no surgical factors related to VAD implantation such as total bypass time, units of blood products received, or location of the device affected the outcome. Notably, there was no difference in infection risk among those who received pulsatile devices and those who received continuous-flow support (Figure 3) . No patients on biventricular support developed infections. Neither time in the intensive care unit nor time in the hospital between admission and the diagnosis of a VAD infection or study termination was associated with an increased risk of VAD infection. Furthermore, no adverse events or non-VADrelated infections on VAD support increased the risk of subsequent VAD infection. Data suggested that the number of bleeding events heightened infection risk (HR=1.14; P=0.06).
Multivariable Analysis
In the multivariable analysis, a history of depression (adjusted HR=2.8; 95% CI, 1.3-6.0; P=0.007) and elevated serum creatinine (adjusted HR=1.7; 95% CI, 1.1-2.7; P=0.025) remained significant predictors of VAD infection (Table 4 ). Figures 4 and 5 show the probability of infection stratified by depression and serum creatinine, respectively.
DT and bridge-to-transplantation patients had the same risk of VAD infection (adjusted HR=1.04; 95% CI, 0.52-2.11; P=0.90), although DT patients were older, had a lower mean albumin, were more likely to have chronic renal dysfunction, and were less likely to have an intra-aortic balloon pump. DT and bridge-to-transplantation patients are compared in Table  III in the online-only Data Supplement.
HeartMate II Patients
Of the 85 patients who received a HeartMate II device, 15 (18%) developed a VAD infection. In univariate and multivariable subgroup analyses, a history of depression and increased total bilirubin were both statistically significantly associated with VAD infection (adjusted HR=3.6; 95% CI, 1.3-9.8; P=0.014; and adjusted HR=1.5; 95% CI, 1.04-2.10; P=0.029, respectively; Figures 1 and 6 show the outcomes of patients with and without VAD infection. A similar proportion (33%-36%) received a cardiac transplant. Overall, 27% of those with VAD infections died compared with 21% of those without infections. In the multivariable analysis (Table 5) , VAD infection increased 1-year mortality (adjusted HR=5.6; 95% CI, 2.4-12.8; P<0.0001).
Transplantation and Survival Outcomes
Other adverse events, including BSIs unrelated to the VAD, respiratory failure, major neurological events (eg, strokes and transient ischemic attacks), and a history of atrial fibrillation, were independent predictors of mortality. Increased baseline serum albumin was protective. Neither depression nor renal dysfunction affected survival. There was no difference in mortality between those who received pulsatile-flow and those who received continuous-flow VADs or among DT versus bridge-to-transplantation patients.
Discussion
This is one of the first large, prospective, multicenter studies to describe the microbiology and epidemiology of VAD infections. Twenty-two percent of 150 VAD recipients experienced VAD infections with a wide-range of pathogens.
The study was designed specifically to identify the earliest signs and symptoms of infection and to obtain concomitant, appropriate microbiological cultures. Each case was carefully reviewed by 1 or 2 infectious disease specialists who used criteria they postulated a priori would be convincing evidence of VAD infection. Most previous studies have been retrospective, single-center studies and/or have not used rigorous criteria to diagnose and describe VAD infections. 6 Recognizing the lack of uniform criteria, the International Society for Heart and Lung Transplantation Infectious Diseases Working Group proposed definitions for VAD infections in 2011, well after the completion of this study. 8 However, this study used similar clinical, microbiological, and histopathological diagnostic requirements. The detailed collection and evaluation of infection-related data in VAD patients with suspected infections are two of the major strengths of this study.
Given the study design, this is probably one of the most accurate and current descriptions of the risk of VAD infection. INTERMACS is a US national registry that records adverse events on mechanical circulatory support. 3 VAD-specific infections involving the pump pocket, driveline, or components of the device in contact with the bloodstream and sepsis are reported to INTERMACS (www.uab.edu/intermacs). Although this registry is important, infections are diagnosed and reported without expert infectious disease oversight. Sepsis may or may not be associated with the VAD or another non-VAD-related infection. Furthermore, INTERMACS has not reported an overall incidence of VAD-specific infection with supporting microbiological data; therefore, this study adds valuable information to that accrued by INTERMACS.
The risk of VAD infection peaked at 18 days after surgery and was lower and fairly constant after 60 days. Our median time to infection was 68 days, considerably later than other studies in which most infections occurred ≈1 month postoperatively. 4, 14, 15 The reason may be that patients are frequently discharged from the hospital and remain on VAD support for longer periods of time. Others have also reported "late" VAD infections, particularly of the driveline. 16 It was hypothesized that those with implanted pulsatile devices would be at higher risk for VAD infection than those with continuous-flow devices (almost all were HeartMate II). Only 14% of subjects in an observational HeartMate II study had a device-related infection, 5 supporting observations by clinicians that infection rates have been declining. A randomized study by Slaughter et al 7 comparing pulsatile-and continuousflow devices found that pulsatile devices had approximately twice the infection rate. Proposed reasons include the fact that implanted pulsatile devices generally have larger surface areas, require more dissection for placement, and have bigger, more rigid drivelines than continuous-flow devices.
If pulsatile devices are associated with increased infection risk, we may not have detected it because the study was underpowered. In addition, the study was conducted when HeartMate II devices were first introduced and Nonetheless, having a continuous-flow device did not decrease the infection risk in this study, and it is plausible that device type does not affect infection outcomes. The decreased infection rate in continuous-flow devices reported by Slaughter et al 7 may not be generalizable for several reasons: Infection was a subgroup analysis; the study included only DT patients; and 33% of patients on pulsatile support required a device exchange compared with 9% of patients on continuous-flow support, which may have increased pulsatile support infection rates. Whether flow is continuous or pulsatile, both devices have a driveline where pathogens can enter and establish infection. In the future, totally implantable devices have the potential to abolish this "Achilles heel." 16 As expected, the vast majority of VAD infections (82%) involved the driveline, although almost two thirds of these infections involved sites such as the pump pocket and/or bloodstream, including 2 cases of septic emboli and 1 case of graft erosion. The driveline serves as an entry point for pathogens and leads to pump pocket and pump housing infections that can become systemic. 6 The HeartMate II study, which followed up subjects on continuous-flow support, reported only driveline infections and sepsis. 5 In that study, it was unclear whether sepsis was associated with a VAD infection, and the follow-up time was limited to 6 months. Our study clearly shows that driveline infections are frequently associated with more extensive involvement of the VAD and concomitant systemic infection.
Staphylococci caused 41% of VAD infections, a finding consistent with past studies. 14, [17] [18] [19] [20] Staphylococci frequently cause device infections, including VAD infections, because they colonize the skin and nose and can adhere to implanted prosthetic material and form biofilms. 6,21-23 A significant proportion of cases were caused by Pseudomonas spp., which can also form biofilms, as well as other Gram-negative enteric organisms. In choosing perioperative antibiotic prophylaxis or empirical treatment of VAD infections, clinicians should consider the antibiograms of the Gram-negative pathogens of their institution. Although candidal infections are not common, they can be serious. 24 The 1 VAD infection caused by Candida glabrata resulted in graft erosion, exsanguination, and death. The efficacy of perioperative fluconazole for preventing these infections is unknown.
Many potential risk factors for VAD infection were evaluated in this study. Although several factors were potentially associated with VAD infection in univariate analysis, only serum creatinine and depression were significant in the multivariable model. For every 1-mg/dL increase in creatinine, there was a 70% increase in the risk of VAD infection. The reason may be that those with renal dysfunction are relatively immunocompromised 25 and generally have a higher severity of illness. In the REMATCH study, a history of renal disease significantly increased the risk of sepsis. 4 Malani et al 26 reported that VAD recipients on hemodialysis were at increased risk for deep surgical site infections. Our study supports these findings.
A notable finding was that patients with a history of depression before VAD surgery had a 3-fold higher risk of subsequent VAD infection. This was statistically significant in the Depression is commonly associated with HF and has been associated with increased morbidity and mortality. [27] [28] [29] [30] [31] [32] [33] Studies involving cardiac surgery patients, including cardiac transplant recipients, have also shown a correlation between depressive symptoms and poor outcomes, including wound infections. [34] [35] [36] [37] VAD recipients are at high risk for depression and other mood disorders; however, there are limited data. [38] [39] [40] Bridgeto-transplantation patients struggle with the uncertainties of donor organ availability and the possibility of dying while awaiting transplantation. 40 Psychiatric conditions may be even more pronounced in DT patients; they have no hope of transplantation and must comply with a complex medical regimen indefinitely, including the technically difficult task of caring for the device. One case report discussed a DT patient who committed suicide by disconnecting his driveline. 41 The effect of depression on VAD complications is even less well understood. The association we found between a history of depression and infection is plausible. Those who were depressed before surgery were likely at higher risk for depression after surgery. Depressed individuals may have poorer compliance with hygiene, device care, rehabilitation, and physician visits. 39 These factors may increase the risk of infection in depressed VAD patients.
VAD infection had serious consequences and increased 1-year mortality 5-to 6-fold. This is understandable given that the majority of infections in the study were ultimately invasive/systemic. Infection also adversely affected survival in other studies in which subjects experienced systemic infections related to the VAD. 4, 18, 42 BSIs unrelated to the VAD, respiratory failure, atrial fibrillation, and neurological adverse events were other independent predictors of mortality in this study. These results are consistent with INTERMACS reports in which infection, neurological events, and respiratory failure were among the 5 leading causes of death in VAD recipients. 3 Sample size was a limitation of this study (22% of 150 infected) and may have restricted our ability to identify additional risks for VAD infection. Potential predictors were specified a priori, but the study was exploratory in nature. Because screening data were not obtained, we could not compare our cohort with the screened and not enrolled population. However, the demographics of our patients and those in the INTERMACS registry are similar, indicating that our population was likely a good representation of the average device recipient. 43 Perioperative antibiotic regimens varied among and within institutions; consequently, we were unable to evaluate the efficacy of different prophylactic antibiotics, including antipseudomonal and antifungal agents. Furthermore, it was difficult to determine specific predictors of VAD infection, which may be attributed to the overall high severity of illness in this patient population. However, baseline renal dysfunction and a history of depression were identified risk factors. Depression increased risk in both HeartMate I and HeartMate II recipients. A further limitation of the study is that depression was not measured by a validated index but rather by history. Regardless, depression is a condition that is frequently overlooked and undertreated. Future research should evaluate this association and identify effective interventions. Efforts to address the mental health of these patients may improve outcomes.
Conclusions
This study demonstrates that VAD infections remain common and are caused by a wide variety of microorganisms. Infections adversely affect survival because they frequently become invasive or systemic. They also may occur later, well after the immediate postoperative period. Although it is generally accepted that continuous-flow devices confer a reduced risk of infection, this was not demonstrated in our study. A totally implantable device may help decrease this risk. Finally, the VAD population suffers numerous adverse events and has a high severity of illness, but depression, baseline elevated creatinine, and elevated bilirubin may increase the chance of infection. Further studies of remediable risk factors such as depression and their treatments are warranted. 
Disclosures
CLINICAL PERSPECTIVE
Ventricular assist devices (VADs) significantly improve quality of life and decrease mortality in patients with advanced heart failure, including those awaiting cardiac transplantation. Unfortunately, VAD implantation is frequently complicated by infection. To the best of our knowledge, this is the first and largest prospective, multicenter VAD study focused on carefully characterizing the microbiology, epidemiology, risk factors, and outcomes of VAD infections. Previous studies have been small, retrospective, or single-center studies and/or have not used rigorous criteria to diagnose and describe VAD infections. Infectious diseases specialists were closely involved in this study, which details the microbiology of these infections. The results have important implications for guiding perioperative prophylaxis regimens and empirical therapy. Furthermore, we show that although the risk of VAD infection is highest immediately after implantation, the risk of infection persists until at least 1 year after surgery. The percutaneous VAD driveline likely serves as an entry point for pathogens. Although most infections involve the driveline, a substantial proportion also involve multiple sites and/or become invasive. These infections are also associated with increased morbidity and mortality, making prevention crucial. Increased serum creatinine and a history of depression were identified as risk factors for VAD infection. Depression is frequently underdiagnosed and undertreated and has been associated with poor outcomes in other populations. Therefore, we have potentially identified a remediable risk factor for VAD infection that requires further investigation. Given the lack of organ donors and the importance of VAD therapy, we hope this research will lead to better diagnosis, treatment, and prevention of VAD infections. 
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